Technology | March 19, 2012

Biomedical Systems Introduces Long-Term ECG Monitoring to Diagnose Atrial Fibrillation

March 19, 2012 - Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia. TruVue's diagnostic benefits include the ability to record and wirelessly transmit every heartbeat for up to 30 days, perform advanced arrhythmia analysis and to provide immediate online access to all transmitted ECG.

TruVue offers electrophysiologists and cardiologists the advantages of both a Holter and cardiac event monitor in one device. Biomedical Systems developed the TruVue system in response to physicians' need for a long-term ECG monitoring device to diagnose symptoms suggestive of cardiac arrhythmia as well as manage the treatment of patients with atrial fibrillation. The patented technology employs cellular communication to transmit recordings of every heartbeat to Biomedical Systems' secure servers. The system's algorithms analyze the incoming data for changes in morphology, rate or rhythm, in addition to patient-triggered alerts when symptoms are experienced. Certified cardiac technicians validate the findings, post reports in real-time and alert physicians based on cardiac events or notification criteria. At any time, physicians can access information online, including any portion of the recorded ECG monitoring and trend reports detailing 24-hour heart-rate and -rhythm abnormalities, including atrial fibrillation.

"TruVue expedites the diagnoses of patients who may have cardiac arrhythmia, including atrial fibrillation, by delivering the most comprehensive long-term view of the heart rhythm," said Jim Ott, Biomedical Systems' cardiology division president. "With TruVue, we provide physicians with the unique ability to review every heartbeat for up to 30 days—combining both algorithm-triggered ECG-recordings and episodes recorded by patients—and immediately access information online without working through support staff."

TruVue has received both its 510(k) clearance from the U.S. Food and Drug Administration and its CE Mark for international sales. Biomedical Systems' Cardiology Division has employed TruVue since 2010, conducting thousands of ECG wireless telemetry procedures.

For more information:

Related Content

HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
iRhythm and Stanford Researchers Develop Deep Learning-Based Cardiac Arrhthymia Detection Algorithm
News | Artificial Intelligence| July 11, 2017
iRhythm Technologies Inc. announced a collaboration with the Stanford Machine Learning Group that has resulted in the...
Abbott SJM Confirm RX Implantable cardiac monitor gains european CE mark approval
News | May 30, 2017
May 30, 2017 — Abbott recently announced European CE mark and first use of the new Confirm Rx Insertable Cardiac Moni
Medtronic Reveal Linq implantable cardiac monitor

The Medtronic Reveal Linq implantable cardiac monitor is the smallest implantable monitor on the market. It is used as a long-term Holter monitor for 24-hour a day, 365-day a year patient monitoring. The device uses wireless connectivity to download the patient data with a patient bedside base unit to send the information over the internet so it is accessible by physicians.

Feature | Atrial Fibrillation| May 16, 2017
May 16, 2017 - The study using small, subcutaneous implantable cardiac monitors for long-term, 24-hour a day monitori
Sponsored Content | Videos | EP Mapping and Imaging Systems| February 01, 2017
This video, provided by Medtronic, demonstrates the CardioInsight electro-anatomical mapping system.
medtronic cardioinsight electromapping system, electoanatomical mapping, noninvasive ep mapping

A screen shot of the waveforms and the the 3-D electo-mapping models created using the noninvasive CardioInsight system.

Technology | EP Mapping and Imaging Systems| February 01, 2017
February 1, 2017 — Medtronic received U.S.
Overlay Init